SG11202100985QA - Ophthalmic compositions and methods for the treatment of eye disorders and skin diseases - Google Patents

Ophthalmic compositions and methods for the treatment of eye disorders and skin diseases

Info

Publication number
SG11202100985QA
SG11202100985QA SG11202100985QA SG11202100985QA SG11202100985QA SG 11202100985Q A SG11202100985Q A SG 11202100985QA SG 11202100985Q A SG11202100985Q A SG 11202100985QA SG 11202100985Q A SG11202100985Q A SG 11202100985QA SG 11202100985Q A SG11202100985Q A SG 11202100985QA
Authority
SG
Singapore
Prior art keywords
treatment
methods
skin diseases
ophthalmic compositions
eye disorders
Prior art date
Application number
SG11202100985QA
Other languages
English (en)
Inventor
Mahesh Kandula
Original Assignee
Cellix Bio Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellix Bio Private Ltd filed Critical Cellix Bio Private Ltd
Publication of SG11202100985QA publication Critical patent/SG11202100985QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C07C237/26Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton of a ring being part of a condensed ring system formed by at least four rings, e.g. tetracycline
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03Monocarboxylic acids
    • C07C57/12Straight chain carboxylic acids containing eighteen carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/33Polycyclic acids
    • C07C63/337Polycyclic acids with carboxyl groups bound to condensed ring systems
    • C07C63/34Polycyclic acids with carboxyl groups bound to condensed ring systems containing two condensed rings
    • C07C63/36Polycyclic acids with carboxyl groups bound to condensed ring systems containing two condensed rings containing one carboxyl group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D339/00Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02Five-membered rings
    • C07D339/04Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG11202100985QA 2018-08-29 2019-07-09 Ophthalmic compositions and methods for the treatment of eye disorders and skin diseases SG11202100985QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201841032406 2018-08-29
PCT/IB2019/055828 WO2020044136A1 (en) 2018-08-29 2019-07-09 Ophthalmic compositions and methods for the treatment of eye disorders and skin diseases

Publications (1)

Publication Number Publication Date
SG11202100985QA true SG11202100985QA (en) 2021-03-30

Family

ID=69644060

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202100985QA SG11202100985QA (en) 2018-08-29 2019-07-09 Ophthalmic compositions and methods for the treatment of eye disorders and skin diseases

Country Status (12)

Country Link
US (1) US20210188817A1 (de)
EP (1) EP3823603A4 (de)
JP (1) JP2021536439A (de)
KR (1) KR20210053926A (de)
AU (1) AU2019333020A1 (de)
BR (1) BR112021003452A2 (de)
CA (1) CA3110248A1 (de)
IL (1) IL280588A (de)
MX (1) MX2021001645A (de)
SG (1) SG11202100985QA (de)
WO (1) WO2020044136A1 (de)
ZA (1) ZA202100656B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102636847B1 (ko) 2020-09-18 2024-02-19 경북대학교 산학협력단 티아민 유도체를 포함하는 이식편대숙주질환 예방 또는 치료용 약학적 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1172110A3 (de) * 2000-07-07 2003-09-17 Basf Aktiengesellschaft Verwendung von Liponsäure zur Verbesserung der Bioverfügbarkeit von Mineralsalzen
US20020198210A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Alpha-2-adrenergic agonist/fatty acid compositions
AU2002256471B2 (en) * 2001-05-03 2007-05-24 Allergan, Inc. Compositions having enhanced pharmacokinetic characteristics
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
WO2008144399A1 (en) * 2007-05-18 2008-11-27 Bausch & Lomb Incorporated COMPLEXES COMPRISING α2-ADRENERGIC RECEPTOR AGONISTS AND COMPOSITIONS
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US8034813B2 (en) * 2008-11-18 2011-10-11 Bausch & Lomb Incorporated Polymorphs of brimonidine pamoate
EP2329849B1 (de) * 2009-11-18 2015-04-29 Galderma Research & Development Kombination aus einem Alpha-2-Adrenozeptor-Agonisten und einem nichtsteroidalen entzündungshemmenden Mittel zur Behandlung oder Prävention einer Entzündungskrankheit der Haut
HUE033143T2 (en) * 2010-03-26 2017-11-28 Galderma Res & Dev Preparations containing brimonidine for the treatment of erythema
US20120076738A1 (en) * 2010-09-28 2012-03-29 Michael Graeber Combination treatment for dermatological conditions
DK2755647T3 (en) * 2011-09-12 2015-10-12 Tassos Georgiou Use of omega fatty acid for medical care
AU2018369853B2 (en) * 2017-11-17 2022-07-14 Cellix Bio Private Limited Compounds, compositions and methods for treatment of eye disorders and skin diseases

Also Published As

Publication number Publication date
AU2019333020A1 (en) 2021-04-29
WO2020044136A1 (en) 2020-03-05
US20210188817A1 (en) 2021-06-24
EP3823603A4 (de) 2022-12-07
AU2019333020A2 (en) 2021-05-06
EP3823603A1 (de) 2021-05-26
JP2021536439A (ja) 2021-12-27
BR112021003452A2 (pt) 2021-05-18
KR20210053926A (ko) 2021-05-12
CA3110248A1 (en) 2020-03-05
MX2021001645A (es) 2021-05-12
ZA202100656B (en) 2021-09-29
IL280588A (en) 2021-03-25

Similar Documents

Publication Publication Date Title
IL262608A (en) Combined treatment of eye disorders and inflammatory diseases
EP3749264C0 (de) Lasertherapie zur behandlung und vorbeugung von augenkrankheiten
PT3377637T (pt) Composições para uso em métodos para o tratamento de ferimentos, transtornos e doenças da pele
IL276383A (en) Treatment of ophthalmological diseases
IL287280A (en) Compounds and methods for the treatment of ocular disorders
EP3876712C0 (de) Screening-verfahren für behandlungen von intraokulare krankheiten oder störungen
IL274234A (en) Preparations and methods for the treatment of eye diseases
IL286636A (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OR DISORDERS RELATED TO KRAS
ZA202006234B (en) Compositions and methods for the treatment of neurological diseases
IL287802A (en) Preparations and methods for the treatment of eye diseases
IL273531A (en) Ophthalmic preparations containing latanoprost for use in the treatment of eye diseases
IL284344A (en) Pharmaceutical preparations for the eyes and methods for the treatment of diseases of the surface of the eye
IL287264A (en) Compounds and methods for the treatment of ocular disorders
EP4054713A4 (de) Zusammensetzungen und verfahren zur behandlung oder vorbeugung von hautkrankheiten und störungen mit lekti
IL289405A (en) Personalized treatment of eye diseases
ZA202002075B (en) Compounds, compositions and methods for treatment of eye disorders and skin diseases
EP3713553A4 (de) Zusammensetzungen und verfahren zur behandlung von augenkrankheiten
EP3644966A4 (de) Behandlung und diagnose von störungen der augenoberfläche
SG11202012473UA (en) Ophthalmic compositions and methods for the treatment of eye disorders
EP4010075A4 (de) Verfahren zur behandlung von apoc3-assoziierten erkrankungen und störungen
ZA202003944B (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
IL280588A (en) Ophthalmic compositions and methods for treating eye problems and skin diseases
IL282898A (en) Ophthalmic compounds and methods for treating skin and eye diseases
PL3515409T3 (pl) Kompleks i kompozycje do leczenia chorób okulistycznych i dermatologicznych
EP3787749A4 (de) Verfahren zur behandlung von netzhauterkrankungen